Premium
Correlation of miR‐181a and three HOXA genes as useful biomarkers in acute myeloid leukemia
Author(s) -
Xu Peipei,
Zhou Di,
Yan Guijun,
Ouyang Jian,
Chen Bing
Publication year - 2020
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13116
Subject(s) - myeloid leukemia , microrna , gene , cancer research , leukemia , bone marrow , medicine , myeloid , biology , pathogenesis , oncology , immunology , genetics
MiR‐181a is a small, noncoding RNA that plays important roles in the pathogenesis and prognosis of acute myeloid leukemia (AML). A group of HOXA genes, including HOXA7, HOXA9, and HOXA11 , has been established as an independent predictor for AML prognosis. In this study, we aimed to investigate the association between miR‐181a and HOXA7, HOXA9, and HOXA11 and explore their roles in predicting prognosis in AML. Patients and Methods Bone marrow samples of 46 untreated AML patients and 9 healthy donors were collected. Mononuclear cells were purified using density‐gradient centrifugation in Ficoll, and quantitative real‐time PCR was used to detect miR‐181a and HOXA gene expression level. Results HOXA7, HOXA9, and HOXA11 were negatively correlated with miR‐181a, and their expression levels varied among AML subtypes, karyotypes, and risk status. Higher miR‐181a and lower HOXA gene expressions were significantly associated with lower risk status and better response to chemotherapy. Conclusion In our study, we found miR‐181a expression was negatively correlated with three HOXA genes and they were associated with AML risk status and prognosis in granulocytic AML. It further supported that miR‐181a could be a useful marker for AML prognosis and possibly worked by regulating HOXA gene clusters.